We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
A pesar del fracaso del estudio confirmatorio, la EMA aprobó alpelisib para el síndrome PROS grave. Analizamos el mecanismo, los riesgos y las perspectivas de Vijoice.
